NCT06085755 2025-12-15
Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer
Samsung Medical Center
Phase 1/2 Recruiting
Clinical Trials
12 trialsNCT06753747 2025-12-03
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
West China Hospital
Phase 1/2 Recruiting
NCT03785249 2025-09-30
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics Inc.
Phase 1/2 Active not recruiting
NCT07010120 2025-06-13
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
West China Hospital
Phase 1/2 Recruiting
NCT06071013 2025-01-23
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
China Medical University Hospital
Phase 1/2 Recruiting
NCT06648096 2024-11-20
AFAN
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Phase 1/2 Recruiting
NCT02768337 2024-01-31
CamBMT1
Cambridge University Hospitals NHS Foundation Trust
Phase 1/2 Terminated
NCT02372006 2021-03-04
Trial of Afatinib in Pediatric Tumours
Boehringer Ingelheim
Phase 1/2 Completed
NCT02450656 2018-08-27
M14AFS
The Netherlands Cancer Institute
Phase 1/2 Unknown
NCT01732640 2018-07-26
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Terminated
NCT02906163 2016-09-19
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
SciClone Pharmaceuticals
Phase 1/2 Unknown
NCT01861223 2014-02-25
Afatinib Plus Nimotuzumb for NSCLC
Samsung Medical Center
Phase 1/2 Unknown